echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Reding Medicine will get "first-in-class" therapy in Greater China...

    Reding Medicine will get "first-in-class" therapy in Greater China...

    • Last Update: 2021-03-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Pharmaceutical Mission, January 7, Reding Pharmaceuticals issued a press release saying it would receive exclusive development and commercial rights to argenx's new drug efgartigimod in Greater China, including Chinese mainland, Hong Kong, Taiwan and Macau, with a total of $175 million in co-payments.
    press release, efgartigimod's first adaptive systemic severe muscle weakness has been filed for listing in the United States.
    Efgartigimod is a "first-in-class" therapy that targets FcRn and is designed to reduce pathogenic IgG antibodies and block the IgG recirculation process.
    FcRn binds are designed to prevent degradation of IgG, so by preventing the binding of IgG to FcRn, IgG antibodies that mediate autoimmune diseases are depleted more quickly, thereby reducing the symptoms of the disease. according to
    , the product can treat autoimmune diseases known to be driven by pathogenic IgG antibodies, including severe muscle weakness (MG), common herpes (PV), immunocompytic platelet reduction (ITP), chronic inflammatory demyelinative multiple neuropathy (CIDP) and so on.
    May 2020, efgartigimod reached the end of its main study in the critical Phase 3 clinical trial ADAPT for patients with anti-acetylcholine(AChR) antibody-positive systemic severe muscle weakness (gMG).
    data showed that 67.7% of AChR antibody-positive patients treated with efgartigimod met the treatment standard (vs 29.7%) for the main study endpoint.
    Efgartigimod reaches the main research endpoint of the ADAPT trial (Photo source: Resources 2) Under the terms of the agreement, Reding Pharmaceuticals will be responsible for the global registered clinical research and development of efgartigimod multiple adaptive disorders in China, as well as the launch of phase 2 validation studies on multiple new adaptations in Greater China to accelerate the development of more autoimmune adaptations of efgartigimod worldwide.
    , Argenx will receive $75 million worth of Reding Pharmaceuticals stock as an advance and $100 million in recent milestones and other payments.
    , founder, chairman and chief executive officer of Efgartigimod, said that efgartigimod was developing a variety of immunodeficirations, and that patients with these diseases were in urgent need of new treatment options.
    expect to bring this "first-in-class" product to a wide range of Chinese patients.
    follow the public number of WeChat
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.